Evaluating Real-World Trends in Metastatic NSCLC Immunotherapy Use

In recent years, immune checkpoint inhibitors targeting the programmed cell death protein-1 or its ligand have transformed the therapeutic landscape for advanced malignancies. Consequently, clinical practice guidelines strongly recommend frontline immune checkpoint blockade, either as monotherapy or combined with chemotherapy, for patients without actionable driver mutations. However, clinical trial results do not always reflect routine community practice. A major retrospective study evaluating real-world metastatic NSCLC immunotherapy use revealed persistent gaps in clinical adoption. The researchers examined data from the Flatiron Health Research Database, analyzing over 13,000 patients diagnosed with metastatic non-small cell lung cancer who initiated first-line systemic treatment between July 2019 and September 2023. Surprisingly, despite clear evidence demonstrating superior overall survival, approximately 25% of eligible individuals received non-immunotherapy-containing regimens. Furthermore, this treatment gap remained remarkably stable across all study years, highlighting a persistent barrier to optimal care. Platinum-based doublet chemotherapy remained the most common alternative choice among clinicians. Therefore, understanding why one in four eligible patients misses frontline immunotherapy is essential for improving clinical oncology outcomes.

Key Patient and Sociodemographic Drivers of Treatment Choices

To identify specific factors driving therapeutic choices, researchers performed a comprehensive multivariable logistic regression analysis. The results demonstrated that demographic variables significantly influence whether a patient receives a non-immunotherapy regimen. Specifically, older age and specific ethnic backgrounds were strongly associated with reduced receipt of immune checkpoint blockade. Clinicians frequently cite advanced age and associated frailty as reasons for withholding aggressive systemic combinations. However, clinical trials consistently demonstrate that older individuals can derive significant survival benefits from tailored immunotherapy protocols without overwhelming toxicity. Additionally, structural healthcare disparities based on patient ethnicity continue to create measurable inequities in treatment delivery. Geographical location also played a critical role in determining therapy selection across different clinical practices. Patients managed in non-academic or community settings were less likely to receive frontline immunotherapies compared to those treated at major academic medical centers. Consequently, these findings emphasize that sociodemographic characteristics heavily dictate therapeutic decisions in routine practice, independent of formal clinical guideline recommendations.

Impact of Tumor Biomarkers and Clinical Disease Characteristics

Beyond sociodemographic influences, specific clinical and biological parameters strongly dictated first-line treatment selection for patients. Programmed death-ligand 1 expression status emerged as one of the most powerful determinants of therapeutic pathways. Specifically, low or negative biomarker expression levels significantly increased the likelihood of clinicians selecting non-immunotherapy options. Although guidelines support combination chemo-immunotherapy regardless of biomarker levels in driver-negative tumors, physicians often remain hesitant to prescribe expensive biological agents when expression is low. Furthermore, prior exposure to immunotherapy in earlier disease stages significantly lowered the probability of re-initiating immune checkpoint inhibitors upon metastatic recurrence. Smoking history also influenced therapeutic choices, as current or former smokers were more likely to receive immunotherapy regimens compared to never-smokers. Disease burden and initial stage at diagnosis further stratified treatment choices across the cohort. Consequently, clinicians appear to rely heavily on baseline biomarker profiles and past clinical course to guide real-world decision-making. Addressing these clinical misconceptions is critical for ensuring that all eligible patients receive optimal evidence-based care.

Addressing Institutional and Structural Barriers to Equitable Care

The persistence of non-immunotherapy regimens in routine clinical settings underscores systemic challenges within oncology delivery networks. Community health systems often face distinct logistical obstacles compared to tertiary academic institutions. For instance, institutional drug reimbursement policies, prior authorization delays, and drug acquisition costs can hinder rapid access to novel immunotherapeutic agents. Furthermore, geographical variation in treatment patterns indicates that local clinical practice habits significantly impact patient management. Practice type heavily influenced prescribing behavior, as community practices demonstrated higher rates of non-immunotherapy utilization. Consequently, bridging the gap between clinical guidelines and everyday practice requires targeted educational initiatives for community oncologists. Health systems must also streamline diagnostic workflows to ensure rapid turnaround times for biomarker testing. Delayed biomarker reporting frequently forces clinicians to initiate standard chemotherapy while awaiting results. Therefore, overcoming institutional hurdles requires coordinated efforts across healthcare administration, clinical teams, and policy makers to democratize access to advanced cancer therapies.

Clinical Implications for Modern Oncology Practice and Guidelines

The findings from this large observational study offer critical insights for practicing oncologists and health policy makers worldwide. Although immune checkpoint blockade has established itself as standard care, real-world practice patterns reveal that delivery remains uneven. Clinicians must carefully re-evaluate decision-making frameworks to ensure that eligible patients are not prematurely excluded from beneficial immunotherapies. Moreover, multidisciplinary oncology teams should establish clear clinical pathways that support the safe administration of immunotherapy in complex populations, such as elderly patients or those with moderate comorbidities. Institutional leaders must address structural inequities and administrative bottlenecks that disproportionately affect underrepresented patient groups. In addition, strengthening clinician education regarding the efficacy of combination chemo-immunotherapy in low biomarker expressors could help bridge current treatment gaps. Ultimately, achieving equitable cancer care requires translating clinical trial success into everyday practice. By addressing clinical, sociodemographic, and institutional barriers, healthcare systems can ensure that all patients with advanced lung cancer benefit from lifesaving therapeutic innovations.

Frequently Asked Questions

Why do some patients with metastatic NSCLC not receive immunotherapy?

Several clinical and structural factors explain why eligible patients do not receive frontline immunotherapy. Clinicians may avoid immunotherapy due to patient age, frailty, low PD-L1 expression, or prior exposure in earlier disease stages. Additionally, institutional reimbursement issues, practice type, geographical disparities, and delayed biomarker testing turnaround times contribute to the continued use of non-immunotherapy chemotherapy regimens in routine clinical practice.

What are the primary factors influencing real-world treatment choices?

Multivariable analysis shows that patient age, ethnicity, geographical region, practice type, smoking history, initial disease stage, and PD-L1 expression status significantly influence therapeutic choices. Community practices and non-academic health centers show higher rates of non-immunotherapy use. Furthermore, clinicians frequently select platinum-based chemotherapy alone when PD-L1 expression is low, despite guidelines recommending combination chemo-immunotherapy for eligible driver-negative metastatic NSCLC patients.

How can health systems improve access to frontline immunotherapy?

Health systems can enhance immunotherapy access by streamlining administrative approval processes, reducing prior authorization delays, and optimizing biomarker testing turnaround times. Furthermore, providing targeted education to community oncologists regarding trial data in older adults and low PD-L1 expressors can align practice with current guidelines. Implementing equitable healthcare access policies will ensure that all eligible patients receive optimal evidence-based therapies.

Disclaimer: This content is for informational and educational purposes only. It is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Refer to the latest local and national guidelines for clinical practice.

References

1. Halloran S et al. Beyond the clinical trial: Real-world treatment patterns and drivers of PD-(L)1 therapy use in first-line metastatic NSCLC. Cancer Treat Res Commun. 2026 Aug 06. doi: undefined. PMID: 42561495.

2. Santorelli ML et al. Real-world PD-L1 testing, first-line therapy for advanced NSCLC, and first-line pembrolizumab monotherapy utilization and outcomes for metastatic NSCLC. Cancer Med. 2025; 14(3): e7890.

3. Miller M et al. Efficacy and safety of first-line immune checkpoint inhibitors in patients with PD-L1 <1% metastatic non-small-cell lung cancer. Taylor & Francis / Curr Med Res Opin. 2025; 41(9): 1421-1435.